Drug Approval | December 29, 2021
U.S. FDA approves Leo Pharma’s Adbry
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
The company has developed the API in house at its R&D center in Hyderabad
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
He has over 22 years of experience in pharmaceutical sales & business development
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
The revolutionary new nano coating is easy to apply and rejects liquid-based contagions like COVID-19/SARS-CoV-2 and variants, influenzas, and rhinoviruses and is available via ready-to-use sprays or pre-treated air filters
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Effectiveness of Covaxin against the Omicron variant is currently being studied
Subscribe To Our Newsletter & Stay Updated
